Tags: Drug.
AEZS-108 (previously AN-152) consists of [D-Lys(6)]LHRH linked to doxorubicin.It is an experimental targeted therapy for various cancers (ovarian endometrial breast bladder prostate) that express LHRH receptor. The U.S. Food and Drug Administration (FDA) has granted it orphan drug status for ovarian cancer.